Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

10:43:18 Europe / Stockholm

Svenska | English

BioStock

Alligator Bioscience: BioStock: Clinical effects observed with Alligator's 4-1BB agonist

2024-03-14 10:41:00

Through its partnership with the US-based biotech Aptevo Therapeutics, Alligator Bioscience is evaluating the bispecific antibody ALG.APV-527 for the treatment of solid tumours in a phase I dose-escalation trial. The companies have announced positive interim results from the dose escalation part of the study, and BioStock spoke with Alligator's CEO Søren Bregenholt to learn more.

Read the article at biostock.se:

Clinical effects observed with Alligator's 4-1BB agonist - BioStock (https://www.biostock.se/en/2024/03/clinical-effects-observed-with-alligators-4-1bb-agonist/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden